BRAIN Biotech AG BNN
XETR · Germany · Health Technology
€2.850.00 (0.00%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Dr. Sven K. Weber will assume the position of CEO on October 1, 2026 Adriaan Moelker will retire at the end of his contract term as scheduled ZWINGENBERG, GERMANY - July 29, 2026 (NEWMEDIAWIRE) - The Supervisory Board of BRAIN Biotech AG ("BRAIN...
Newly patented CRISPR nuclease exhibits high activity in various prokaryotic and eukaryotic organisms Patent now opens up significant potential for further commercial use through licensing BRAIN Biotech offers its technology for strain optimizat...
ZWINGENBERG, GERMANY - March 11, 2026 (NEWMEDIAWIRE) - At today's Annual General Meeting of BRAIN Biotech AG (Frankfurt Stock Exchange / BNN / ISIN DE0005203947 / WKN 5203949), shareholders approved all agenda items with a broad majority. Dr. Ursu...
Growth driven by demand for natural, clean-label foods, the sector is seeing robust expansion, particularly in emerging economies. Notably, the beverage application segment is experiencing significant growth due to rising beer consumption and innovation, as highlighted by IFF's launch of enzyme solutions like BCLEAR and DIAZYME NOLO. The dry formulation segment also stands out for its stability and cost benefits, preferred in bakery and processed food industries. Europe's dominant market positio
BRAIN Biotech AG ( ETR:BNN ) just released its latest yearly report and things are not looking great. It definitely...
We feel now is a pretty good time to analyse BRAIN Biotech AG's ( ETR:BNN ) business as it appears the company may be...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.